Q-omics provides the consensus-scored KRT17P8 profile across patient tissues and cancer cell-line models. KRT17P8 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, KRT17P8 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, KRT17P8 RNA expression shows 16,812 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, LUSC, and LSCC as cancer lineages where KRT17P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT17P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT17P8 survival associations across molecular data types. KRT17P8 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT17P8 RNA expression–survival associations across cancer types. High KRT17P8 expression shows unfavorable associations in LAML and DLBC, but favorable associations in UCS, HNSC, ESCA and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for KRT17P8 RNA expression.
This table summarizes KRT17P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT17P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT17P8 shows lower tumor expression in LUSC, THCA, CHOL and LUAD and higher tumor expression in KIRC and HNSC. The LUSC box plot shows higher KRT17P8 RNA expression in normal versus tumor tissue (log2 FC = −0.358, t-test p < 0.001).
This table shows molecular features associated with KRT17P8 in patient tissues and cancer cell lines. In patient samples, KRT17P8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
